JP2009507835A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507835A5
JP2009507835A5 JP2008530022A JP2008530022A JP2009507835A5 JP 2009507835 A5 JP2009507835 A5 JP 2009507835A5 JP 2008530022 A JP2008530022 A JP 2008530022A JP 2008530022 A JP2008530022 A JP 2008530022A JP 2009507835 A5 JP2009507835 A5 JP 2009507835A5
Authority
JP
Japan
Prior art keywords
neuritin
composition
antibody
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008530022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/035324 external-priority patent/WO2007030820A2/en
Publication of JP2009507835A publication Critical patent/JP2009507835A/ja
Publication of JP2009507835A5 publication Critical patent/JP2009507835A5/ja
Pending legal-status Critical Current

Links

JP2008530022A 2005-09-09 2006-09-11 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 Pending JP2009507835A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71576605P 2005-09-09 2005-09-09
PCT/US2006/035324 WO2007030820A2 (en) 2005-09-09 2006-09-11 Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013239723A Division JP6019334B2 (ja) 2005-09-09 2013-11-20 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作

Publications (2)

Publication Number Publication Date
JP2009507835A JP2009507835A (ja) 2009-02-26
JP2009507835A5 true JP2009507835A5 (enExample) 2009-11-05

Family

ID=37836580

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008530022A Pending JP2009507835A (ja) 2005-09-09 2006-09-11 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2013239723A Active JP6019334B2 (ja) 2005-09-09 2013-11-20 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2016083897A Pending JP2016183163A (ja) 2005-09-09 2016-04-19 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2018089059A Pending JP2018197227A (ja) 2005-09-09 2018-05-07 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013239723A Active JP6019334B2 (ja) 2005-09-09 2013-11-20 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2016083897A Pending JP2016183163A (ja) 2005-09-09 2016-04-19 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作
JP2018089059A Pending JP2018197227A (ja) 2005-09-09 2018-05-07 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作

Country Status (6)

Country Link
US (1) US20100040636A1 (enExample)
EP (2) EP1931384A4 (enExample)
JP (4) JP2009507835A (enExample)
AU (1) AU2006287315B2 (enExample)
CA (1) CA2621992C (enExample)
WO (1) WO2007030820A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2719267A1 (en) * 2008-04-25 2009-10-29 New York Blood Center, Inc. Abi1/hssh3bp1 conditional knockout mouse
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
US20150258096A1 (en) * 2012-10-10 2015-09-17 The Regents Of The University Of California Methods and compositions for treatment of th2-mediated and th17-mediated diseases
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
US9926565B2 (en) * 2014-09-23 2018-03-27 Oregon Health & Science University Aptamer-RNAi therapeutic compositions
EP3687561A4 (en) * 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
WO2020146772A1 (en) * 2019-01-11 2020-07-16 The Johns Hopkins University Neuritin regulation of t cell anergy and t regulatory cell function
WO2025241119A1 (zh) * 2024-05-22 2025-11-27 深圳理工大学(筹) 融合蛋白及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH04501510A (ja) 1989-07-25 1992-03-19 セル　ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
JPH04505546A (ja) 1990-02-09 1992-09-24 アスラブ　ソシエテ　アノニム 写真平版マイクロ製造法を用いて製造した放射場静電マイクロモーター及び前記マイクロモーターの製造方法
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ZA924244B (en) 1991-06-18 1993-12-10 Lilly Co Eli Rapid synthesis and screening of peptide mimetics
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5817784A (en) * 1996-08-09 1998-10-06 Amgen Inc. Neurogene
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP2003524406A (ja) * 1999-06-02 2003-08-19 ジェネンテック・インコーポレーテッド 腫瘍細胞成長阻害のための組成物及び方法
AU2002363231A1 (en) * 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
AU2003275240A1 (en) * 2002-09-24 2004-04-23 Massachusetts Institute Of Technology Methods and compositions for soluble cpg15
CA2499843A1 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity

Similar Documents

Publication Publication Date Title
Seyfrid et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Tran et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
JP7696658B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
JP6683990B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
Omer-Javed et al. Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells
JP2021151249A (ja) 腫瘍抗原ｎｙ−ｅｓｏ−１のｍｈｃ ｉおよびｍｈｃ ｉｉ拘束性エピトープに対する、癌の併用ｔ細胞受容体遺伝子療法
Look et al. CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines
JP2019516352A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
JP2022511735A5 (enExample)
JP6942466B2 (ja) 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
ES2967879T3 (es) Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9
CN114174495A (zh) 肿瘤浸润淋巴细胞疗法及其用途
CN110627909A (zh) 一种特异性活化nk细胞的嵌合抗原受体及其应用
Hussein et al. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma
JP2018531016A (ja) 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
WO2024017362A1 (zh) 靶向gprc5d和/或bcma的嵌合抗原受体及其应用
JP2009507835A5 (enExample)
Niu et al. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells
WO2018082590A1 (zh) 肿瘤免疫治疗靶标及其应用
Deuse et al. Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells
WO2017035251A1 (en) T cells modified to overexpress c-myb
CN121263436A (zh) 用于治疗病症的工程化免疫细胞，构造及其方法
CN112262212B (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
Xiong et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors
CN107326027A (zh) 一种rna嵌合体及其用途